- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 213/64 - One oxygen atom attached in position 2 or 6
Patent holdings for IPC class C07D 213/64
Total number of patents in this class: 955
10-year publication summary
|
67
|
74
|
78
|
58
|
65
|
65
|
51
|
54
|
51
|
24
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Epizyme, Inc. | 370 |
27 |
| Abbvie Inc. | 1801 |
20 |
| Bristol-myers Squibb Company | 4893 |
17 |
| Boehringer Ingelheim International GmbH | 4648 |
15 |
| Mitsui Chemicals Agro, Inc. | 88 |
14 |
| F. Hoffmann-La Roche AG | 7921 |
12 |
| Bayer Pharma AG | 1047 |
12 |
| Inflazome Limited | 85 |
12 |
| Takeda Pharmaceutical Company Limited | 2709 |
10 |
| Nippon Soda Co., Ltd. | 894 |
10 |
| Calico Life Sciences LLC | 96 |
9 |
| Eli Lilly and Company | 3844 |
8 |
| Taisho Pharmaceutical Co., Ltd. | 870 |
8 |
| Unigen, Inc. | 111 |
8 |
| Pfizer Inc. | 3381 |
7 |
| Celgene Quanticel Research, Inc. | 163 |
7 |
| Gilead Sciences, Inc. | 2037 |
7 |
| Eisai R&D Management Co., Ltd. | 1231 |
7 |
| Merck Sharp & Dohme LLC | 3741 |
7 |
| Genentech, Inc. | 3980 |
6 |
| Other owners | 732 |